Article Text

Download PDFPDF

Association of haptoglobin genetic polymorphism with overall survival in advanced castration-resistant prostate cancer patients with personalized peptide vaccination
  1. Nobukazu Komatsu1,
  2. Xiaoliang Pang2,
  3. Hiromitsu Araki2,
  4. Yoshiro Koda1,
  5. Kimiko Soejima1,
  6. Tetsuro Sasada1,
  7. Kosuke Tashiro2,
  8. Satoru Kuhara2 and
  9. Kyogo Itoh1
  1. Aff1 grid.410781.bKurume University Kurume-shi Japan
  2. Aff2 grid.177174.30000000122424849Kyushu University Fukuoka-shi Japan

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Although a peptide vaccination is potentially useful for cancers, there are some patients who do not show clinically beneficial response to this treatment. Previously, we have demonstrated gene expression profiling of pre-vaccination peripheral blood mononuclear cells in advanced castration-resistant prostate cancer patients with personalized peptide vaccination, and we have found some genes related with overall survival. In this study, we sequenced the upstream region of Haptoglobin (HP), which is the most significant q-value in a univariate Cox regression analysis (q-value=0.001) and highly expressed in patients with poor clinical response. Genetic polymorphism of the upstream of HP was identified and this polymorphism classifies patients with good or poor clinical response to a peptide vaccination. Our results suggested that mRNA level and genetic polymorphism of HP is related to the prognosis of advanced castration-resistant prostate cancer patients treated with peptide vaccination.